OM1

OM1 to Present Research on Multiple Sclerosis at ACTRIMS Forum 2024

Retrieved on: 
Tuesday, February 27, 2024

The poster will focus on the use of an AI based estimation model used to help characterize disease progression in multiple sclerosis (MS) subtypes using real-world data (RWD).

Key Points: 
  • The poster will focus on the use of an AI based estimation model used to help characterize disease progression in multiple sclerosis (MS) subtypes using real-world data (RWD).
  • WHEN: The presentation will be held on the first day of ACTRIMS Forum 2024 on Thursday, February 29 between 6:00 – 7:30 pm ET.
  • WHY: To effectively monitor disease progression in patients with MS, the measurement of disability is an important component.
  • For insights specific to OM1’s work with multiple sclerosis, including the company’s PremiOM MS dataset, visit the website page here .

Kalderos Names Two Industry Veterans to Executive Leadership Roles

Retrieved on: 
Wednesday, January 17, 2024

CHICAGO, Jan. 17, 2024 /PRNewswire/ -- Data infrastructure and analytics company Kalderos, creator of the world's first Drug Discount Management platform, today announced the hiring of two senior executives to drive its operational excellence, product innovation, and stakeholder satisfaction.

Key Points: 
  • Pharmaceutical companies spend more than $250 billion annually in discounts and rebates, and 2022's Inflation Reduction Act mandates even more pricing concessions.
  • Kalderos has built a platform that uses transparent data to bring drug discount stakeholders together, enabling discounts and rebates to be paid more accurately and efficiently.
  • "We are fortunate to have two healthcare technology and pharmaceutical industry veterans, each with decades of respective experience, join our executive leadership team as we continue to rapidly grow across our customer base and platform capabilities," said Kalderos CEO Angie Franks.
  • In addition to several other healthcare technology leadership positions, his pharmaceutical industry experience includes surpassing numerous revenue goals and developing successful teams as director of sales at Covance (now LabCorp) and district sales manager at Scherling-Plough.

OM1 Launches Asthma and Chronic Rhinosinusitis Datasets to Expand Real-World Evidence in Respiratory and ENT

Retrieved on: 
Monday, October 2, 2023

OM1 , a leading real-world data, AI, and technology company with a focus on chronic diseases, announced the launch of two new clinical datasets, Chronic Rhinosinusitis (CRS) and Asthma .

Key Points: 
  • OM1 , a leading real-world data, AI, and technology company with a focus on chronic diseases, announced the launch of two new clinical datasets, Chronic Rhinosinusitis (CRS) and Asthma .
  • Rapidly growing, the CRS and Asthma datasets each follow approximately 500,000 patients in the U.S.
  • The research-grade, real-world data available in the OM1 Respiratory & ENT Network is built with an exclusive partnership between OM1 and the American Academy of Otolaryngology and Head and Neck Surgery Foundation (AAO-HNSF).
  • Millions of Americans are impacted by respiratory diseases, and the number continues to rise as respiratory illnesses become more common and air quality declines.

OM1 Launches Hidradenitis Suppurativa Dataset to Expand Real-World Evidence in Dermatology

Retrieved on: 
Thursday, September 21, 2023

OM1 a leading real-world data, AI and technology company with a focus on chronic diseases, today announced the continued expansion of its Dermatology Network to include Hidradenitis Suppurativa (HS) , a systemic inflammatory disease, enhancing the dataset with almost 26,000 patient records.

Key Points: 
  • OM1 a leading real-world data, AI and technology company with a focus on chronic diseases, today announced the continued expansion of its Dermatology Network to include Hidradenitis Suppurativa (HS) , a systemic inflammatory disease, enhancing the dataset with almost 26,000 patient records.
  • Studies continue to show the link between skin conditions and mental health.
  • With one in four Americans impacted by a skin disease, combined with the increasing mental health epidemic, it’s critical to uncover and introduce solutions that will ultimately improve health outcomes.
  • “People are going years without an accurate diagnosis of their dermatological conditions, resulting in a worsening of both the disease and the patient’s mental health,” said Stefan Weiss, MD, MBA, FAAD Managing Director of Dermatology at OM1.

OM1 Appoints Shawn Bates as Chief Commercial Officer

Retrieved on: 
Tuesday, September 19, 2023

OM1 , a leading real-world data, AI and technology company with a focus on chronic diseases, today announced the appointment of Shawn Bates as Chief Commercial Officer.

Key Points: 
  • OM1 , a leading real-world data, AI and technology company with a focus on chronic diseases, today announced the appointment of Shawn Bates as Chief Commercial Officer.
  • Bates will work cross-functionally to steer OM1’s commercial strategy – including sales, marketing, and commercial operations – widening the company’s reach across the healthcare and life sciences industries.
  • In these roles, Bates championed and scaled customer-centric commercial frameworks, yielded successive years of robust growth, and unveiled a fresh go-to-market approach that saw the expansion and launch of new services.
  • "The healthcare industry is at an exciting and pivotal moment as leaders across the ecosystem integrate advanced technology, AI and machine learning throughout business operations to advance how therapies and treatments are delivered to patients,” said Shawn Bates, Chief Commercial Officer, OM1.

OM1 Launches Parkinson’s Disease Premium Dataset to Expand Real-World Evidence in Neuroscience

Retrieved on: 
Thursday, September 7, 2023

OM1 , the leading real-world data and technology company focused on chronic conditions, today announced the launch of its Parkinson’s Disease (PD) premium dataset and the enhancement of its Mental Health & Neuroscience Real-World Data Network .

Key Points: 
  • OM1 , the leading real-world data and technology company focused on chronic conditions, today announced the launch of its Parkinson’s Disease (PD) premium dataset and the enhancement of its Mental Health & Neuroscience Real-World Data Network .
  • The dataset includes more than 7,000 patients prospectively followed by neurologists in hundreds of clinics across all 50 states.
  • To enrich the data, OM1 extracts relevant information from treating clinician notes using its unique artificial intelligence (AI) and language modeling capabilities.
  • To learn more about the largest mental health and neuroscience data network in the U.S., please email [email protected] .

OM1 to Expedite and Improve Research With New Study Automation Platform & Evidence Generation Solution

Retrieved on: 
Monday, June 26, 2023

OM1 , a leading real-world data and technology company with a focus on chronic conditions, today announced the launch of OM1 Aspen , its novel, automated study platform for evidence generation.

Key Points: 
  • OM1 , a leading real-world data and technology company with a focus on chronic conditions, today announced the launch of OM1 Aspen , its novel, automated study platform for evidence generation.
  • Traditional research relies on extensive use of manual processes that are burdensome to healthcare providers and patients, driving biases in enrollment and delays in time to study completion and insights.
  • With automation as its guiding principle, OM1 Aspen is transforming research with flexible, reusable infrastructure; leveraging advanced data acquisition, processing, and linkage technologies; streamlining large studies; and creating powerful evidence networks.
  • OM1 Aspen’s technology platforms approach to generating real-world data dramatically:
    In addition, OM1 Aspen meets the high bar required for using real-world data and generating real-world evidence for regulatory purposes, including being fit-for-purpose, transparent, and traceable.

American Academy of Dermatology launches innovative project to improve outcomes for patients with life-threatening pustular psoriasis

Retrieved on: 
Thursday, June 22, 2023

The AAD's new Generalized Pustular Psoriasis Education Initiative aims to transform the care of these patients by leveraging the power of data in the Academy's DataDerm™ dermatology patient registry.

Key Points: 
  • The AAD's new Generalized Pustular Psoriasis Education Initiative aims to transform the care of these patients by leveraging the power of data in the Academy's DataDerm™ dermatology patient registry.
  • The project will connect DataDerm's 50 million deidentified patient encounters with OM1's AI-based Patient Finder™ tool to improve understanding of GPP patients' journey, treatment patterns, disease progression, and outcomes.
  • "The American Academy of Dermatology is committed to excellence in dermatology and finding innovative approaches to improve patient care," said AAD President Terrence A. Cronin Jr., MD., FAAD.
  • Findings from the first phase of the project will be shared at the American Academy of Dermatology's 2024 Annual Meeting, March 8 – 12 in San Diego.

Altis Labs Raises US $6 Million in Seed Funding Co-Led by Debiopharm and Benchstrength to Advance AI Platform for Clinical Trials

Retrieved on: 
Wednesday, June 21, 2023

Altis Labs, Inc. (“Altis”), the computational imaging company accelerating clinical trials with artificial intelligence, today announces the closing of its US $6 million seed financing.

Key Points: 
  • Altis Labs, Inc. (“Altis”), the computational imaging company accelerating clinical trials with artificial intelligence, today announces the closing of its US $6 million seed financing.
  • “We are thrilled to partner with Benchstrength and Debiopharm,” said Felix Baldauf-Lenschen, Co-Founder and CEO of Altis.
  • Altis was founded with the belief that imaging is the richest source of clinical data but is vastly underutilized.
  • Funding will be used to scale the development of Nota, Altis’ AI-powered imaging biomarker platform, across solid tumor types and therapeutic areas.

OM1 Launches Analytics to Deliver Mental Health & Immunology Insights on Prescriber Trends and Therapy Effectiveness

Retrieved on: 
Wednesday, May 24, 2023

OM1 , a leading real-world data, outcomes, and technology company with a focus on chronic conditions, today announced the launch of two new Real-World Analytics products – Prescriber Trends and Comparative Outcomes – to provide standardized, ready-to-access analyses of trends in treatment and outcomes in immunology and mental health condition areas.

Key Points: 
  • OM1 , a leading real-world data, outcomes, and technology company with a focus on chronic conditions, today announced the launch of two new Real-World Analytics products – Prescriber Trends and Comparative Outcomes – to provide standardized, ready-to-access analyses of trends in treatment and outcomes in immunology and mental health condition areas.
  • A combination of market trends – an emphasis on personalized medicine, the rise of new modalities and treatment options, and regulatory challenges – means that pharmaceutical companies are constantly amending commercial strategies to keep up.
  • The healthcare landscape continues to evolve, but one thing remains constant – the need for deep, actionable, and data-backed insights.
  • Comparative Outcomes: leverages extensive patient outcomes data extracted from unstructured clinical notes to provide information on the effectiveness and comparative effectiveness of medications across various outcomes over time.